ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
Journal: Clinical Cancer Research. Vol 17, No 23, December 2011, doi: 10.1158/1078-0432.CCR-11-1648
Veröffentlichung: Dezember 2011
Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model
Journal: Journal of Thoracic Oncology, Vol 6, No 12, December 2011, doi: 10.1097/JTO.0b013e3182307ede
Veröffentlichung: Dezember 2011
Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET
Journal: Journal of Nuclear Medicine, Vol 52, No 12, December 2011, doi:10.2967/jnumed.111.094458
Veröffentlichung: Dezember 2011
A crucial requirement for Hedgehog signaling in small cell lung cancer
Journal: Nature Medicine, Vol 17, No 11, October 2011, doi: 10.1038/nm.2473
Veröffentlichung: Oktober 2011
Personalized therapy of lung cancer cokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles
Journal: Clinical Pharmacokinetics, Vol 50, No 9, September 2011 doi: 10.2165/11593320-000000000-00000
Veröffentlichung: September 2011